Janus Henderson Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Janus Henderson Group’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.2M	Buy	757,435 +66,806	+10%	+$976K	0.01%	729
2025 Q4	$11M	Sell	690,629 -350,492	-34%	-$4.97M	﹤0.01%	730
2025 Q3	$11.5M	Buy	1,041,121 +819,585	+370%	+$8.95M	0.01%	721
2025 Q2	$1.88M	Buy	221,536 +172,205	+349%	+$1.38M	﹤0.01%	1314
2025 Q1	$409K	Hold	49,331	–	–	﹤0.01%	2058
2024 Q4	$443K	Hold	49,331	–	–	﹤0.01%	2091
2024 Q3	$361K	Hold	49,331	–	–	﹤0.01%	2179
2024 Q2	$281K	Hold	49,331	–	–	﹤0.01%	2238
2024 Q1	$247K	Hold	49,331	–	–	﹤0.01%	2319
2023 Q4	$444K	Hold	49,331	–	–	﹤0.01%	2046
2023 Q3	$383K	Hold	49,331	–	–	﹤0.01%	2074
2023 Q2	$478K	Hold	49,331	–	–	﹤0.01%	2002
2023 Q1	$540K	Buy	49,331 +29,619	+150%	+$261K	﹤0.01%	1970
2022 Q4	$85.3K	Hold	19,712	–	–	﹤0.01%	2360
2022 Q3	$148K	Hold	19,712	–	–	﹤0.01%	1963
2022 Q2	$198K	Hold	19,712	–	–	﹤0.01%	2313
2022 Q1	$244K	Hold	19,712	–	–	﹤0.01%	2343
2021 Q4	$451K	Buy	+19,712	New	+$467K	﹤0.01%	1953

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Janus Henderson Group's AUPH Position: Q1 2026 in Review

Janus Henderson Group increased its Aurinia Pharmaceuticals (AUPH) stake by 9.7% in Q1 2026, buying an estimated $976K and bringing the position to 757,435 shares worth $11.2M. The position accounts for 0.01% of the portfolio, ranked #729.

Janus Henderson Group first reported a position in AUPH in Q4 2021 and has held it in 18 quarters since. The position peaked at $11.5M in Q3 2025. 260 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

Janus Henderson Group held 757,435 shares of Aurinia Pharmaceuticals worth $11.2M as of Q1 2026.
Janus Henderson Group bought 66,806 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $976K.
Aurinia Pharmaceuticals made up 0.01% of Janus Henderson Group's portfolio in Q1 2026, its #729 holding.
Janus Henderson Group first reported a position in Aurinia Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
Janus Henderson Group's Aurinia Pharmaceuticals position peaked at $11.5M in Q3 2025.
260 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.